Research programme: Chronic urticaria therapeutics - Enanta Pharmaceuticals
Latest Information Update: 17 May 2024
At a glance
- Originator Enanta Pharmaceuticals
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic urticaria